Biosimilars

Tendering Insights From Game Theory

The increase in tendering as well as the entry of multiple biosimilars is disrupting the healthcare market in Europe, with plenty of new players and procedures. This blog looks at…

Read Full Article

placeholder

Europe’s evolving landscape for biosimilar medicines

Co-authored by Todor Finkov, Manager, Pricing, Tenders & Contracts In the EU healthcare landscape, three major influences have advanced the current position of biosimilar medicines: Advances in the biologics manufacturing…

Read Full Article

The Biosimilar Uptick

On July 18, 2018, the FDA published its guidance for biosimilars, “Labeling for Biosimilar Products.” This guidance provides an overview of the FDA’s recommendations for biosimilar labeling, so that prescribers…

Read Full Article

Biosimilars-The New Market Access Opportunity?

Biosimilars are on the agenda of several players in the pharmaceutical industry. Several companies’ new leg of growth seems to be the creation of a biosimilar franchise. The question is…

Read Full Article